Please login to the form below

Not currently logged in
Email:
Password:

Curis looks to MedImmune and Takeda for new hires

Tania Chander and Jaye Viner join cancer specialist

Curis has made two senior appointments in the form of Dr Jaye Viner as chief medical officer and executive VP and Dr Tania Chander as VP, product development.

Dr Viner joins the cancer specialist from Millennium – Takeda's oncology-focused subsidiary – where she was medical director.

It is the second high profile departure from Millennium in recent weeks, following Dr Claire Thom's switch to fellow Japanese pharma firm Astellas to lead oncology development.

According to Curis, Dr Viner will be responsible for the leadership of the company's clinical development strategy and efforts to further the development of its pipeline of proprietary drug candidates. 

These include CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor.
Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

The company is looking to be more independent in its research approach, however, and believes that Dr Viner will help achieve this goal.

“We believe that Jaye's molecular oncology knowledge, combined with broad experience across clinical oncology development, will tremendously enhance our internal capabilities,” said Ali Fattaey, Curis' president and chief operating officer.

In addition to her time at Millennium, Dr Viner has experience in oncology drug development at AstraZeneca subsidiary MedImmune and the National Cancer Institute and the National Institutes of Health.

Curis Tania ChanderDr Chander (pictured) joins from MedImmune where she spent several years in increasingly senior roles across multiple therapy areas.

Most recently she was associate director, product development team lead, where she provided leadership to oncology product teams on strategy and clinical development for various oncology drug candidates.

She also has experience at Bristol-Myers Squibb as part of the virology team.

Article by
Thomas Meek

15th August 2013

From: Research

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....